Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

aeli pharmaceutical company focused primarily on acquisitions and development of late clinical-stage new formulations of existing drugs. Ondansetron is sold under the trade name Zofran©.

RedHill is the exclusive licensee of SCOLR's CDT platform for application to extended release tablet formulations of ondansetron.  Mr. Turner said, "We are encouraged that RedHill continues in its efforts to bring an extended release ondansetron tablet to market, and are pleased to continue our involvement in that process through these development services."In addition, in November SCOLR announced the award of approximately $250,000 in federal funds under the Therapeutic Discovery Project conducted by the Department of the Treasury and the Department of Health and Human Services.  The funds were awarded in connection with qualifying development expenses incurred during 2009 and earlier this year.

Included as part of the Patient Protection and Affordable Care Act of 2010, the Therapeutic Discovery Project program provided a tax credit to encourage investments in new therapies to prevent, diagnose, and treat acute and chronic diseases. Companies such as SCOLR that cannot currently use a tax credit were allowed to apply for a cash grant in lieu of a tax credit. SCOLR was awarded the grant funds primarily in connection with expenditures on its program for development of an extended release formulation of ibuprofen, as well as its programs for development of new ondansetron and peramivir formulations.

Third Quarter 2010 compared to Third Quarter 2009 Financial ResultsTotal revenues for the quarter ended September 30, 2010 were $124,000, a decrease of 53% compared to $262,000 for the same period in 2009. This decrease is due to a decrease in royalty income from our relationship with Perrigo.  Effective January 2010, commensurate with the amendment of our agreement with Perrigo, the royalty rate Perrigo pays us on sales of licensed products decr
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... Israel , February 27, 2015 /PRNewswire/ ... baut sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz ... aus -     ... Technologies, die ein neuartiges Herzüberwachungssystem für Patienten ... heute bekannt, dass sie ein Finanzierungsvorhaben über ...
(Date:2/26/2015)... SANTA CLARA, Calif. , Feb. 27, 2015  Finesse ... Finesse Solutions announced the expansion of ... The opening is planned for mid-March and access for ... access from the A-563, and located adjacent to the ... occupied by the Finesse automation engineering team and allow Finesse ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2New Finesse Office in United Kingdom 2
... EMERYVILLE, Calif., Oct. 26, 2011 Bionovo, Inc. (Nasdaq: ... the discovery and development of safe and effective treatments ... has started to the Phase 3 pivotal clinical trial ... Menerba™ (MF101) among a cohort of postmenopausal women for ...
... Inc. (Nasdaq: NBIX ) announced today that the ... the Nasdaq market closes on Monday,  October 31, 2011.  Neurocrine ... discuss its financial results and provide a Company update Monday ... p.m. Pacific Time). Participants can access the live ...
Cached Medicine Technology:Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 2Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 3Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes 4
(Date:3/1/2015)... 28, 2015 CrossFit Attollo is a CrossFit ... offering a special discount to new members. Now through ... a three month contract will receive their fourth month half ... cost members $440. The three month contract is only ... then the fourth month comes in at only $55. The ...
(Date:2/28/2015)... 28, 2015 Gerald “Solutionman” Haman surveyed ... or barriers to innovative thinking. “The #1 block ... lack of tools,” reports Haman, who created the Thinkubator ... of people felt that they did not have enough ... and resources to stimulate innovation. , Solutionman’s monthly “Accelerating ...
(Date:2/28/2015)... 2015 Mew and Company, a Vancouver ... now provide business consulting services in addition to a ... planning and succession planning. Company finances are a complicated ... On top of this, complex Canadian tax laws can ... As a result, Mew and Company works to advise ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... its annual awards at the International Symposium on Malignant ... be held at the Hyatt Regency Bethesda in Bethesda, ... their dedicated work and commitment to the mission to ... Year Award will be presented to Miriam Ratner. Miriam ...
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... Boniva, Zometa does not apply to obese women, however , ... drugs used to prevent and treat osteoporosis might reduce the ... study, which included 6,000 Wisconsin women aged 20 to 69, ... Boniva and Zometa for more than two years were 40 ...
... ... ... , ... , , , ...
... ... a new partnership with leading SolidWorks and Agile PLM reseller GoEngineer to distribute DesignState ... "best-in-class" tools to manage engineering data and collaborate across the enterprise with Oracle,s ... ...
... ... of a new resource that may help put some of your questions to bed. BestFoodFacts.org, ... the country to weigh in on what’s true, plausible, unknown, misguided or just plain false. ... (PRWEB) March 5, 2010 ...
... ... that society’s obligation and moral responsibility to remedy the tragic legacy of decades of ... follow? , ... March 5, 2010 -- The Mesothelioma Applied Research Foundation today publicly praised the United ...
... 39th Annual Meeting of the American Association for ... Convention Center in Washington, DC, lead researcher M. ... poster of a study titled "Epithelial-to-Endothelial Transition: An ... and a team of researchers have reported that ...
Cached Medicine News:Health News:Certain Bone Drugs May Lower Breast Cancer Risk 2Health News:Christiana Care Health System Wins National Award for Innovation 2Health News:Christiana Care Health System Wins National Award for Innovation 3Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 2Health News:Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState 3Health News:BestFoodFacts.org -- Food, Fiber and Fuel Questions Answered 2Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 2Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 3
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver Chondroplastic blade, sharp on two sides, curved, sterile...
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
... accurate testing of large oculomotor ... Fits all standard trial frames. ... of thin optical quality acrylic ... includes a display box. Available ...
Medicine Products: